Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.40 |
| ▸ | BACE1 | P56817 | 7/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27430671 | 0.92 | KISS1R (0.36) | KISS1RMMP9MMP8MMP12LMNA | |
| SCHEMBL27430678 | 0.92 | KISS1R (0.36) | KISS1RMMP9MMP8MMP12LMNA | |
| SCHEMBL30724708 | 0.91 | BACE1 (0.45) | KISS1RBACE1CTSDMMP9MMP8 | |
| SCHEMBL27429147 | 0.91 | KISS1R (0.37) | KISS1RMMP9MMP8MMP12LMNA | |
| SCHEMBL27428793 | 0.90 | KISS1R (0.39) | KISS1RBACE1CTSDCTSLCTSB | |
| SCHEMBL27389168 | 0.90 | KISS1R (0.39) | KISS1RBACE1CTSDCTSLCTSB | |
| SCHEMBL30918360 | 0.90 | KISS1R (0.39) | KISS1RBACE1CTSDCTSLCTSB | |
| SCHEMBL27428938 | 0.90 | KISS1R (0.43) | KISS1RBACE1CTSDMMP9MMP8 | |
| SCHEMBL27429704 | 0.89 | MMP12 (0.36) | KISS1RMMP9MMP8MMP12LMNA | |
| SCHEMBL27430986 | 0.88 | KISS1R (0.39) | KISS1RBACE1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | KISS1R 1618/4885BACE1 1969/4885CTSD 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.